December 5, 2018 / 1:32 PM / 6 days ago

BRIEF-Roche Says Kadcyla Cuts Risk Of Breast Cancer Recurring

Dec 5 (Reuters) - Roche Holding AG:

* ROCHE’S KADCYLA CUT RISK OF DISEASE RECURRING BY HALF COMPARED TO HERCEPTIN IN PEOPLE WITH HER2-POSITIVE EARLY BREAST CANCER WITH RESIDUAL DISEASE AFTER NEOADJUVANT TREATMENT

* KADCYLA CUT RISK OF DISEASE RECURRING BY HALF COMPARED TO HERCEPTIN IN PEOPLE WITH HER2-POSITIVE EARLY BREAST CANCER WITH RESIDUAL DISEASE AFTER NEOADJUVANT TREATMENT

* AT THREE YEARS, 88.3% OF PEOPLE TREATED WITH KADCYLA IN ADJUVANT HER2-POSITIVE EARLY BREAST CANCER SETTING DID NOT HAVE THEIR BREAST CANCER RETURN COMPARED TO 77.0% TREATED WITH HERCEPTIN

* DATA FROM PHASE III KATHERINE STUDY WILL BE SUBMITTED TO HEALTH AUTHORITIES GLOBALLY Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below